Evidence map›Paper›PMID 37173116›Full record

ArticleBMJ open2023

Rationale and Design of the Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion Trial (CAPITAL-RAPTOR).

Pietro Di Santo, Omar Abdel-Razek, Richard Jung, Simon Parlow, Anthony Poulin, Jordan Bernick, Baylie Morgan, Lisa Robinson, Hannah Feagan, Jilliane Wade and 11 more

Registry-linked trialOpen access · goldAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ open, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03630055 (Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03630055 phase3terminatednot on this map

Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion

TypeinterventionalSponsorOttawa Heart Institute Research CorporationRan2018 to 2025Enrolled930ConditionsRadial Artery OcclusionArmsRivaroxaban 15 MG Oral Tablet [Xarelto]
3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 6 institutions in 3 countries.

Pietro Di SantoCAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.
Omar Abdel-RazekCAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.
Richard JungCAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.
Simon ParlowCAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.
Anthony PoulinDivision of Cardiology, Quebec Heart and Lung Institute, Quebec, Québec, Canada.
Jordan BernickCardiovascular Research Methods Centre, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.
Baylie MorganCAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.
Lisa RobinsonCAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.
Hannah FeaganCAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.
Jilliane WadeCAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.
Cheng Yee GohCAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.
Kuljit SinghDepartment of Cardiology, Gold Coast University Hospital, Southport, Queensland, Australia.
Michael FroeschlCAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.
Marino LabinazCAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.
Dean A FergussonClinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.ORCID 0000-0002-3389-2485
Doug CoyleSchool of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada.
Kwadwo KyeremantengDepartment of Critical Care, University of Ottawa, Ottawa, Ontario, Canada.
Joseph AbunassarDivision of Cardiology, Queen's University, Kingston, Ontario, Canada.
George A WellsSchool of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada.
Trevor SimardDepartment of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota, USA.
Benjamin HibbertCAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada bhibbert@ottawaheart.ca.ORCID 0000-0003-0906-1363
University of Ottawa · CAGold Coast Hospital · AUMayo Clinic · USMontreal Heart Institute · CAOttawa Hospital · CAQueen's University · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionTransradial access (TRA) has rapidly emerged as the preferred vascular access site for coronary angiography and percutaneous coronary intervention. Radial artery occlusion (RAO) remains as an important complication of TRA as it precludes future ipsilateral transradial procedures. While intraprocedural anticoagulation has been studied extensively, the definitive role of postprocedural anticoagulation has not yet been established. METHODS AND ANALYSIS: The Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion trial is a multicentre, prospective, randomised, open-label, blinded-endpoint design study investigating the efficacy and safety of rivaroxaban to reduce the incidence of RAO. Eligible patients will undergo randomisation to receive either rivaroxaban 15 mg once daily for 7 days or to no additional postprocedural anticoagulation. Doppler ultrasound to assess radial artery patency will be performed at 30 days. ETHICS AND DISSEMINATION: The study protocol has been approved by the Ottawa Health Science Network Research Ethics Board (approval number 20180319-01H). The study results will be disseminated via conference presentations and peer-reviewed publications. TRIAL REGISTRATION NUMBER: NCT03630055.

Indexed as

Arterial Occlusive DiseasesPercutaneous Coronary InterventionAnticoagulantsCardiac CatheterizationCoronary AngiographyHumansMulticenter Studies as TopicProspective StudiesRadial ArteryRandomized Controlled Trials as TopicRivaroxabanTreatment OutcomeAnticoagulantsRivaroxabancardiologycoronary interventionischaemic heart diseasevascular medicine

Identifiers

PMID37173116
PMCPMC10186464
OpenAlexW4376276256

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.